1. Home
  2. BAFN vs MAIA Comparison

BAFN vs MAIA Comparison

Compare BAFN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$7.92

Market Cap

40.6M

Sector

Finance

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.20

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
MAIA
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
44.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
BAFN
MAIA
Price
$7.92
$1.20
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.9K
449.5K
Earning Date
10-30-2025
11-07-2025
Dividend Yield
2.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,931,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.40
$0.87
52 Week High
$19.75
$2.74

Technical Indicators

Market Signals
Indicator
BAFN
MAIA
Relative Strength Index (RSI) 37.72 53.94
Support Level $8.05 $1.07
Resistance Level $8.07 $1.25
Average True Range (ATR) 0.10 0.12
MACD 0.04 0.04
Stochastic Oscillator 24.39 55.93

Price Performance

Historical Comparison
BAFN
MAIA

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: